|
05 Sep 2025 |
Cipla
|
Consensus Share Price Target
|
1571.00 |
1677.33 |
- |
6.77 |
buy
|
|
|
|
|
24 May 2024
|
Cipla
|
FundsIndia
|
1571.00
|
1776.00
|
1486.45
(5.69%)
|
|
Buy
|
|
|
|
|
13 May 2024
|
Cipla
|
ICICI Direct
|
1571.00
|
1645.00
|
1414.65
(11.05%)
|
Target met |
Buy
|
|
|
|
|
13 May 2024
|
Cipla
|
SMC online
|
1571.00
|
|
1414.65
(11.05%)
|
|
Results Update
|
|
|
|
|
13 May 2024
|
Cipla
|
Axis Direct
|
1571.00
|
1550.00
|
1414.65
(11.05%)
|
Target met |
Buy
|
|
|
We have BUY on the stock
|
|
14 Mar 2024
|
Cipla
|
Sharekhan
|
1571.00
|
1700.00
|
1488.45
(5.55%)
|
Target met |
Buy
|
|
|
|
|
29 Jan 2024
|
Cipla
|
BOB Capital Markets Ltd.
|
1571.00
|
1576.00
|
1336.85
(17.52%)
|
Target met |
Buy
|
|
|
BJAUT: Healthy revival but priced in; downgrade to SELL. TVSL: On a fast track raise to BUY. SBICARD: Asset quality concerns persist; downgrade to HOLD. LAURUS: Challenges galore cut to SELL. CIPLA: Healthy revenue growth, strong margins. MAHGL: Volume growth accelerating, reiterate BUY. DCBB: NII sequentially flat on high interest cost. SBILIFE: ULIP-led growth; maintains market leadership
|
|
29 Jan 2024
|
Cipla
|
Axis Direct
|
1571.00
|
1515.00
|
1336.85
(17.52%)
|
Target met |
Buy
|
|
|
The company launching new products in the market. gSynbicort and one Peptide ($300-400 Mn) product have been already launched in the last quarter and the company has planned to launch 4 more peptides in FY25E.
|
|
26 Jan 2024
|
Cipla
|
Prabhudas Lilladhar
|
1571.00
|
1400.00
|
1369.65
(14.70%)
|
Target met |
Accumulate
|
|
|
|
|
25 Jan 2024
|
Cipla
|
SMC online
|
1571.00
|
|
1369.65
(14.70%)
|
|
Results Update
|
|
|
|
|
25 Jan 2024
|
Cipla
|
BOB Capital Markets Ltd.
|
1571.00
|
1576.00
|
1369.65
(14.70%)
|
Target met |
Buy
|
|
|
Q3 strong with EBITDA beat of 9% over consensus, though impairment charges of Rs 1.9bn limited PAT outperformance vs consensus
|